Search

Your search keyword '"Beardsley, James R"' showing total 25 results
Start Over Author "Beardsley, James R"
25 results on '"Beardsley, James R"'

3. Analysis of infections among patients with historical culture positive for extended-spectrum beta-lactamase (ESBL)–producing Escherichia coli or Klebsiella pneumoniae: Is ESBL-targeted therapy always needed?

Author

Stone, Tyler J., primary, DeWitt, Michael, additional, Johnson, James W., additional, Beardsley, James R., additional, Munawar, Iqra, additional, Palavecino, Elizabeth, additional, Luther, Vera P., additional, Ohl, Christopher A., additional, and Williamson, John C., additional

Published
2023
Full Text
View/download PDF

5. Reply to Young, Ochi, and Marimuthu

Author

Williamson, John C., Gibbs, Haley G., Ohl, Christopher A., Johnson, James W., Beardsley, James R., Luther, Vera P., and Rokas, Kristina E. E.

Published
2016

11. Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States

Author

Rhodes, Nathaniel J, primary, Dairem, Atheer, additional, Moore, William J, additional, Shah, Anooj, additional, Postelnick, Michael J, additional, Badowski, Melissa E, additional, Michienzi, Sarah M, additional, Borkowski, Jaime L, additional, Polisetty, Radhika S, additional, Fong, Karen, additional, Spivak, Emily S, additional, Beardsley, James R, additional, Hale, Cory M, additional, Pallotta, Andrea M, additional, Srinivas, Pavithra, additional, and Schulz, Lucas T, additional

Published
2021
Full Text
View/download PDF

14. Multicenter point-prevalence evaluation of the utilization and safety of drug therapies for COVID-19

Author

Rhodes, Nathaniel J., primary, Dairem, Atheer, additional, Moore, William J., additional, Shah, Anooj, additional, Postelnick, Michael J., additional, Badowski, Melissa E., additional, Michienzi, Sarah M., additional, Borkowski, Jaime L., additional, Polisetty, Radhika S., additional, Fong, Karen, additional, Spivak, Emily S., additional, Beardsley, James R., additional, Hale, Cory M., additional, Pallotta, Andrea M., additional, Srinivas, Pavithra, additional, and Schulz, Lucas T., additional

Published
2020
Full Text
View/download PDF

18. Impact of an Interprofessional Collaborative Quality Improvement Initiative to Decrease Inappropriate Thyroid Function Testing.

Author

Bradshaw, Alyssa B., Bonnecaze, Alex K., Burns, Cynthia A., and Beardsley, James R.

Subjects
THYROID disease diagnosis, THYROID gland function tests, THYROTROPIN, HOSPITAL medical staff, THYROXINE, UNNECESSARY surgery, RETROSPECTIVE studies, PATIENTS, COST control, MEDICAL care costs, PRE-tests & post-tests, INTERPROFESSIONAL relations, QUALITY assurance, DESCRIPTIVE statistics, EMERGENCY medical services, EDUCATIONAL outcomes
Abstract

Background: Published data show that thyroid function laboratory tests are often ordered inappropriately in the acute care setting, which leads to unnecessary costs and inappropriate therapy decisions. Pilot data at our institution indicated that approximately two-thirds of the thyroid-stimulating hormone (TSH) laboratories were unnecessary, correlating to a potential cost avoidance of more than $20,000 annually. The purpose of this study was to improve the appropriateness of thyroid function test ordering with a multipronged initiative. Methodology : This controlled, single-center, before and after study included inpatients or emergency department (ED) patients at Wake Forest Baptist Medical Center who were at least 18 years of age and had a TSH level ordered during the study period. Patients with a history of thyroid cancer were excluded. The initiative included an electronic ordering intervention, direct education of providers (medical residents, attendings, and clinical pharmacists), and distribution of pocket information cards with appropriate ordering criteria. The primary outcome was the number and percentage of inappropriate TSH tests ordered before and after implementing the 3 interventions. Secondary outcomes included cost savings, inappropriate changes in thyroid therapy based on improperly ordered tests, and the number of free T4 lab tests ordered on patients with a TSH within the therapeutic range. Results : All 3 interventions were implemented, except for education of ED residents and faculty, who chose to forgo the direct education component. Inappropriate ordering of TSH levels decreased from 63 to 50 (13% reduction, P =.062) after implementation. Inappropriate TSH ordering decreased across all services, except in the ED. Inappropriate Free T4 orders decreased from 191 to 133 (30% reduction, P =.01). There were no therapy changes based on inappropriate TSH orders. Extrapolated annual cost savings were approximately $6,000. Conclusion : This multipronged interprofessional collaborative quality improvement initiative was associated with a nonstatistically significant reduction in inappropriate TSH orders, statistically significant reduction in inappropriate free T4 orders, and cost savings. There was a reduction in inappropriate ordering across all services except the ED, which may have been due the ED not participating in the direct education component of the initiative. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

20. Reply to Young, Ochi, and Marimuthu

Author

Williamson, John C., primary, Gibbs, Haley G., additional, Ohl, Christopher A., additional, Johnson, James W., additional, Beardsley, James R., additional, Luther, Vera P., additional, and Rokas, Kristina E. E., additional

Published
2015
Full Text
View/download PDF

24. New Diagnostic Techniques Highlight the Need for Negative Controls.

Author

Raoult, Didier, Williamson, John C., Gibbs, Haley G., Johnson, James W., Beardsley, James R., Ohl, Christopher A., Luther, Vera P., and Rokas, Kristina E. E.

Subjects
RESPIRATORY syncytial virus infections, DIAGNOSIS methods, THERAPEUTICS
Abstract

A letter to the editor is presented regarding need for negative controls in diagnostic techniques for infections by the respiratory syncytial virus.

Published
2016
Full Text
View/download PDF

25. Multicenter point-prevalence evaluation of the utilization and safety of drug therapies for COVID-19.

Author

Rhodes NJ, Dairem A, Moore W, Shah A, Postelnick MJ, Badowski ME, Michienzi SM, Borkowski JL, Polisetty RS, Fong K, Spivek ES, Beardsley JR, Hale CM, Pallotta AM, Srinivas P, and Schulz LT

Abstract

Background: There are currently no FDA-approved medications for the treatment of COVID-19. At the onset of the pandemic, off-label medication use was supported by limited or no clinical data. We sought to characterize experimental COVID-19 therapies and identify safety signals during this period., Methods: We conducted a non-interventional, multicenter, point prevalence study of patients hospitalized with suspected/confirmed COVID-19. Clinical and treatment characteristics within a 24-hour window were evaluated in a random sample of up to 30 patients per site. The primary objective was to describe COVID-19 targeted therapies. The secondary objective was to describe adverse drug reactions (ADRs)., Results: A total of 352 patients from 15 US hospitals were included. Most patients were treated at academic medical centers (53.4%) or community hospitals (42.6%). Sixty-seven patients (19%) were receiving drug therapy in addition to supportive care. Drug therapies included hydroxychloroquine (69%), remdesivir (10%), and interleukin-6 inhibitors (9%). Five patients (7.5%) were receiving combination therapy. Patients with a history of asthma (14.9% vs. 7%, p=0.037) and those enrolled in clinical trials (26.9% vs. 3.2%, p<0.001) were more likely to receive therapy. Among those receiving COVID-19 therapy, eight patients (12%) experienced an ADR, and ADRs were more commonly recognized in patients enrolled in clinical trials (62.5% vs 22%, OR=5.9, p=0.028)., Conclusions: While we observed high rates of supportive care for patients with COVID-19, we also found that ADRs were common among patients receiving drug therapy including in clinical trials. Comprehensive systems are needed to identify and mitigate ADRs associated with experimental COVID-19 therapies.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results